View Older Stories View More Recent Stories

Dec 9, 2024 09:10AM Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Nov 26, 2024 09:22AM Lexaria Bioscience (LEXX) Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Nov 26, 2024 09:20AM Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Nov 25, 2024 09:00AM Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Nov 20, 2024 09:05AM ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Nov 14, 2024 09:12AM Lexaria Bioscience (LEXX) Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Nov 14, 2024 09:11AM Lexaria Bioscience (LEXX) Signs Contract for New DehydraTECH GLP-1 Biodistribution Study
Nov 14, 2024 09:10AM Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Nov 7, 2024 09:15AM Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Oct 24, 2024 09:12AM Lexaria Bioscience (LEXX): Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 24, 2024 09:10AM Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 22, 2024 09:22AM Lexaria Bioscience (LEXX): Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 22, 2024 09:20AM Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 15, 2024 08:25AM Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Oct 9, 2024 09:05AM Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Oct 8, 2024 09:20AM Lexaria Updates Current GLP-1 Market
Oct 1, 2024 09:27AM Lexaria Bioscience (LEXX) Appoints Michael Shankman as Chief Financial Officer
Oct 1, 2024 09:25AM Lexaria Appoints Michael Shankman as Chief Financial Officer
Sep 27, 2024 09:24AM Lexaria Bioscience (LEXX) Receives Independent Review Board Approval to Begin Human Pilot Study #3
Sep 27, 2024 09:20AM Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Sep 5, 2024 10:00AM Lexaria Releases Strategic Letter from the Outgoing CEO
Sep 5, 2024 09:05AM Lexaria Bioscience (LEXX) Appoints Richard Christopher as CEO
Sep 5, 2024 09:00AM Lexaria Welcomes Industry Veteran as New CEO
Sep 3, 2024 08:30AM Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Aug 29, 2024 09:28AM Lexaria Bioscience (LEXX) Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Aug 29, 2024 09:25AM Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Aug 27, 2024 09:20AM First Results from Lexaria's Second GLP-1 Human Pilot Study
Aug 22, 2024 09:23AM Lexaria Bioscience (LEXX): Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Aug 22, 2024 09:20AM Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Aug 21, 2024 09:00AM Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Aug 19, 2024 09:08AM Lexaria Bioscience (LEXX) Announces Positive Results from Molecular Characterization Study
Aug 19, 2024 09:05AM Positive Results from Lexaria's Molecular Characterization Study
Jul 16, 2024 09:22AM Lexaria Bioscience (LEXX) Announces Plans for Growth
Jul 16, 2024 09:20AM Lexaria Preparing For Strategic Growth
Jul 8, 2024 09:13AM Lexaria Bioscience (LEXX) Receives New Patents for Antiviral Drug Delivery and for Treating Epilepsy
Jul 8, 2024 09:10AM Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Jun 18, 2024 09:00AM Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
View More Recent Stories View Older Stories